| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Infectious Diseases,
Department of Immunology, and
Hartwell Center for Bioinformatics and Biotechnology, St. Jude Children’s Research Hospital, Memphis, TN 38105;
Walter and Eliza Hall Institute of Medical Research,
¶ Ludwig Institute for Cancer Research, Royal Melbourne Hospital, Parkville, Victoria, Australia;
|| Laboratory of Molecular Cell Biology, Rockefeller University, New York, NY 10016;
# Center for the Development of Molecular Target Drugs, Cancer Research Institute, Kanazawa University, Kanazawa, Ishikawa, Japan;
** Division of Therapeutic Proteins, Center for Drug Evaluation & Research, U.S. Food and Drug Administration, Bethesda, MD 20892;
Division of Metabolism, Endocrinology and Diabetes, Department of Medicine, University of Michigan Medical School, Ann Arbor, MI 48109; and
* Department of Immunology, M.D. Anderson Cancer Center, Houston, TX 77030
Although many cytokine receptors generate their signals via the STAT3 pathway, the IL-10R appears unique in promoting a potent anti-inflammatory response (AIR) via STAT3 to antagonize proinflammatory signals that activate the innate immune response. We found that heterologous cytokine receptor systems that activate STAT3 but are naturally refractory (the IL-22R), or engineered to be refractory (the IL-6, leptin, and erythropoietin receptors), to suppressor of cytokine signaling-3-mediated inhibition activate an AIR indistinguishable from IL-10. We conclude that the AIR is a generic cytokine signaling pathway dependent on STAT3 but not unique to the IL-10R.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 This work was supported in part by National Institutes of Health Grant AI062921, the Sandler Program for Asthma Research, The Cancer Center Support CORE Grant P30 CA 21765, and by the American Lebanese Syrian Associated Charities.
2 Address correspondence and reprint requests to Dr. Peter J. Murray, Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105. E-mail address: peter.murray{at}stjude.org
3 Abbreviations used in this paper: AIR, anti-inflammatory response; BMDM, bone marrow-derived macrophage; SOCS, suppressor of cytokine signaling; EPO, erythropoietin; EpoR, erythropoietin receptor; ELR, EpoR-leptin R hybrid.
This article has been cited by other articles:
|
|
 |
|
  M. Muhlbauer, P. M. Chilton, T. C. Mitchell, and C. Jobin Impaired Bcl3 Up-regulation Leads to Enhanced Lipopolysaccharide-induced Interleukin (IL)-23P19 Gene Expression in IL-10-/- Mice J. Biol. Chem., May 23, 2008; 283(21): 14182 - 14189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Liu, Y. S. Lee, C.-R. Yu, and C. E. Egwuagu Loss of STAT3 in CD4+ T Cells Prevents Development of Experimental Autoimmune Diseases J. Immunol., May 1, 2008; 180(9): 6070 - 6076. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Kalliolias and L. B. Ivashkiv IL-27 Activates Human Monocytes via STAT1 and Suppresses IL-10 Production but the Inflammatory Functions of IL-27 Are Abrogated by TLRs and p38 J. Immunol., May 1, 2008; 180(9): 6325 - 6333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kennedy Norton, B. Barnstein, J. Brenzovich, D. P. Bailey, M. Kashyap, K. Speiran, J. Ford, D. Conrad, S. Watowich, M. R. Moralle, et al. IL-10 Suppresses Mast Cell IgE Receptor Expression and Signaling In Vitro and In Vivo J. Immunol., March 1, 2008; 180(5): 2848 - 2854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Owaki, M. Asakawa, N. Morishima, I. Mizoguchi, F. Fukai, K. Takeda, J. Mizuguchi, and T. Yoshimoto STAT3 Is Indispensable to IL-27-Mediated Cell Proliferation but Not to IL-27-Induced Th1 Differentiation and Suppression of Proinflammatory Cytokine Production J. Immunol., March 1, 2008; 180(5): 2903 - 2911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. El Kasmi, A. M. Smith, L. Williams, G. Neale, A. Panopolous, S. S. Watowich, H. Hacker, B. M. J. Foxwell, and P. J. Murray Cutting Edge: A Transcriptional Repressor and Corepressor Induced by the STAT3-Regulated Anti-Inflammatory Signaling Pathway J. Immunol., December 1, 2007; 179(11): 7215 - 7219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Qin, K. L. Roberts, S. A. Niyongere, Y. Cong, C. O. Elson, and E. N. Benveniste Molecular Mechanism of Lipopolysaccharide-Induced SOCS-3 Gene Expression in Macrophages and Microglia J. Immunol., November 1, 2007; 179(9): 5966 - 5976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Gong, R. Ishida-Takahashi, E. C. Villanueva, D. C. Fingar, H. Munzberg, and M. G. Myers Jr. The Long Form of the Leptin Receptor Regulates STAT5 and Ribosomal Protein S6 via Alternate Mechanisms J. Biol. Chem., October 19, 2007; 282(42): 31019 - 31027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nishinakamura, Y. Minoda, K. Saeki, K. Koga, G. Takaesu, M. Onodera, A. Yoshimura, and T. Kobayashi An RNA-binding protein {alpha}CP-1 is involved in the STAT3-mediated suppression of NF-{kappa}B transcriptional activity Int. Immunol., May 1, 2007; 19(5): 609 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Murray The JAK-STAT Signaling Pathway: Input and Output Integration J. Immunol., March 1, 2007; 178(5): 2623 - 2629. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
